The global sentiment towards medical cannabis is changing with an increasing number of jurisdictions legislating in favour of the use of Cannabis for medical purposes. Medical cannabis use is now approved in Austria, France, Germany, Israel, Italy, the Netherlands, USA (25 states), Canada, Czech Republic, North Korea, Spain, Uruguay, Chilé, Turkey and Australia.

There is significant clinical evidence demonstrating the medical benefits of medicinal cannabis in respect to the treatment of chronic pain, neuropathic pain, as anti-emetics in the treatment of chemotherapy-induced nausea and vomiting and for improving patient-reported multiple sclerosis spasticity.

Each of these markets represent a significant opportunity with over 5 million patients suffering from these conditions in Australia alone.